Full Breakdown
GSK's Emma Walmsley Receives Significant Pay Rise in Final Year as CEO
3/5/2026, 10:47:41 PM
Overview of Pay Increase
Emma Walmsley, the outgoing chief executive of GlaxoSmithKline (GSK), received a near-50% pay rise, bringing her total remuneration to £15.6 million in her final year leading the company. This increase included a salary of £1.4 million, an annual bonus of £3.5 million, and £10 million from share bonuses, attributed to a significant rise in GSK's share price. The share price for the long-term incentive plan increased from £14.43 in 2024 to £21.65 in 2025.
Company Performance and Strategic Decisions
GSK's financial performance under Walmsley's leadership showed notable growth, with turnover rising by 7% to £32.7 billion and pre-tax profit more than doubling to £7.4 billion in 2025. The company achieved five major product approvals in the U.S., contributing to improved shareholder value. Walmsley emphasized a target of at least £40 billion in sales by 2031, a goal reiterated by her successor, Luke Miels, who took over on January 1, 2026. Miels has already initiated several strategic moves, including a £1.6 billion acquisition of a Californian biotech firm focused on severe food allergies.
Background and Context
Walmsley, who previously led GSK's consumer healthcare division, oversaw the company's most significant restructuring in two decades, including the 2022 spinoff of its consumer arm, now known as Haleon. Her tenure was marked by increased investment in research and development, particularly in respiratory, immunology, inflammation, and cancer treatments, as well as vaccines. Despite facing challenges, including a campaign by activist investor Elliott Management to oust her, Walmsley maintained her position and focused on enhancing GSK's competitive edge.
Official Statements & Responses
A GSK spokesperson stated that Walmsley's remuneration was reflective of "another year of very strong performance for GSK against stretching targets," highlighting the company's sales and profit growth as well as the successful product approvals. Luke Miels, in his new role, has expressed intentions to demonstrate "scientific courage" and agility in GSK's operations to produce more competitive products.
Criticism & Opposition
Despite the positive performance metrics, some critics may question the appropriateness of such a substantial pay rise amidst broader economic challenges and public scrutiny of executive compensation in the pharmaceutical industry. The disparity in pay increases between Walmsley and her peers, such as Pascal Soriot of AstraZeneca, who received a 6.4% increase to £17.7 million, may also draw attention to the growing concerns over income inequality within corporate structures.
What's Next
As GSK transitions under Miels' leadership, the company is expected to continue pursuing aggressive growth strategies while addressing the challenges of a slowing sales growth forecast. The focus will remain on innovation and competitive product development in the pharmaceutical sector.
